EPO (Erythropoietin)

FDA-approved context Healing & Recovery 3 sources

Erythropoietin (EPO) is a glycoprotein hormone that regulates red blood cell production. While primarily known and FDA-approved for treating anemia associated with chronic kidney disease and chemotherapy, research has also uncovered its potent tissue-protective and neuroprotective properties. These secondary effects have made it a subject of ongoing study for conditions like stroke, traumatic brain injury, and neurodegenerative diseases.

01Dosing reference

Amount

50-100 Units/kg (Clinical anemia dosing)

Frequency

1-3 times per week

Cycle

Continuous until target hemoglobin is reached, with ongoing maintenance

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

EPO Receptor Binding

Binds to the erythropoietin receptor (EPOR) on the surface of erythroid progenitor cells and various non-hematopoietic cells.

JAK2/STAT5 Activation

Activates the JAK2/STAT5 signaling pathway, promoting cell survival, proliferation, and differentiation.

Erythropoiesis and Tissue Protection

Stimulates red blood cell production to improve oxygen delivery, while also exerting anti-apoptotic and anti-inflammatory effects in tissues like the brain and heart.

03Human evidence

Effective treatment for anemia

Numerous large-scale clinical trials have demonstrated EPO's efficacy in raising hemoglobin levels and reducing the need for blood transfusions in patients with chronic kidney disease and cancer.

Potential neuroprotection in stroke

Some clinical trials have investigated EPO for acute ischemic stroke, showing mixed results regarding functional recovery and safety, with some studies noting an increased risk of adverse events.

04Preclinical evidence

Neuroprotection in animal models

In rodent models of traumatic brain injury and spinal cord injury, EPO administration reduced neuronal apoptosis, decreased inflammation, and improved functional outcomes.

Cardioprotection during ischemia

Animal studies of myocardial infarction have shown that EPO can reduce infarct size and improve cardiac function when administered around the time of the ischemic event.

05What is known vs. unknown

Reasonably established

EPO is the primary regulator of red blood cell production in the body.
Recombinant human EPO (rhEPO) is FDA-approved for specific types of anemia.
Beyond hematopoiesis, EPO receptors are found in the brain, heart, and other tissues, mediating protective effects.
Misuse of EPO for athletic performance enhancement carries severe cardiovascular risks.

Unknowns & limits

The optimal dosing and timing for EPO's neuroprotective and cardioprotective effects in humans remain unclear.
High doses of EPO used for tissue protection may increase the risk of thrombosis and tumor progression, complicating its clinical translation for these uses.

06Safety & regulatory context

Regulatory statusRecombinant human EPO is an FDA-approved prescription medication for treating anemia caused by chronic kidney disease, chemotherapy, or HIV treatment. However, it carries black box warnings for increased risks of death, myocardial infarction, stroke, venous thromboembolism, and tumor progression when dosed to target hemoglobin levels above 11 g/dL. Common side effects include hypertension, joint pain, and muscle spasms. Due to its ability to increase oxygen-carrying capacity, EPO is banned by the World Anti-Doping Agency (WADA) and its illicit use in sports can lead to life-threatening hyperviscosity of the blood.

07Compared with HIF-PH Inhibitors (e.g., Roxadustat)

EPO (Erythropoietin) vs. HIF-PH Inhibitors (e.g., Roxadustat)

Key difference

HIF-PH inhibitors stimulate endogenous EPO production by stabilizing hypoxia-inducible factors, whereas rhEPO directly provides exogenous hormone.

When researchers discuss each

Researchers discuss rhEPO for direct, rapid correction of anemia or targeted tissue protection, while HIF-PH inhibitors are explored as oral alternatives that mimic the body's natural response to hypoxia.

08Glossary

Erythropoiesis

The process of producing red blood cells.

Hypoxia

A condition in which the body or a region of the body is deprived of adequate oxygen supply.

Apoptosis

Programmed cell death, a process that EPO helps prevent in certain tissues to promote survival.

09Knowledge check

Q1What is the primary physiological role of Erythropoietin (EPO)?

Q2Why is the use of EPO for neuroprotection challenging in clinical settings?

Q3Given the dossier's summary of clinical trials of EPO for acute ischemic stroke, which interpretation best reflects the human evidence presented?

Q4Which statement best describes the key mechanistic and research-context difference between recombinant human EPO (rhEPO) and HIF-PH inhibitors in the dossier?

Q5Which regulatory or safety statement about recombinant human EPO is supported by the dossier?

10Sources

More in Healing & Recovery

See all

BPC-157

Healing & Recovery

Early human

BPC-157 is a synthetic peptide sequence based on a protective compound naturally found in human gastric juice. Research suggests it has significant regenerative properties, promoting the healing of tendons, ligaments, muscles, and the gastrointestinal tract by accelerating angiogenesis and modulating growth factors.

250-500 mcg

TB-500 (Thymosin Beta-4)

Healing & Recovery

Early human

TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4. Research indicates it plays a crucial role in tissue repair, wound healing, and reducing inflammation by upregulating actin, a vital protein for cell structure and movement.

2.0 - 2.5 mg per injection

KPV

Healing & Recovery

Early human

KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). Research highlights its potent anti-inflammatory and antimicrobial properties, making it a promising candidate for conditions like inflammatory bowel disease, skin disorders, and wound healing.

200-500 mcg/day

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.